FDA Inspection
Srdan VerstovsekSrdan Verstovsek – FDA Inspection, Aug 11, 2017
Record Details
This FDA Inspection record concerns Srdan Verstovsek, with an inspection on August 11, 2017, issued by the Dallas District Office, covering human drugs.
- Office
- Dallas District Office
- People
- Leighton K. Ngai (Company Rep)
- Rachel M. Skeete (Issuing Officer)
View Company Profile
ID · ce84275b-3a2c-44f3-91a9-20bb57f3f64e
Inspection Facts
- Inspection number
- 1021218
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
FDA Citations
4- 21 CFR 312.60FD-1572, protocol compliance
- 21 CFR 312.60Informed consent
- 21 CFR 312.62(a)Accountability records
- 21 CFR 312.62(b)Case history records- inadequate or inadequate
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Srdan Verstovsek
1| Date | Classification | Office | Project area |
|---|---|---|---|
| September 18, 2014 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Srdan Verstovsek
- FDA Inspection 902563 - 2014-09-18
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.